Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

NCT06317558 · clinicaltrials.gov ↗

RECRUITING

Status

4000

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Neoadjuvant immunotherapy
DRUG: Other drugs for neoadjuvant treatment

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences